FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549	9
------------------------	---

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

	OMB APPROVAL								
	OMB Number: 3235-0								
	Estimated average burden								
- 1	hours per response:	0.5							

11. Nature

Instruction 1(b).			Filed pursuant to Section 16(a) of the Securities Exchange Act of 193	34
			or Section 30(h) of the Investment Company Act of 1940	
1. Name and Address Rolph Timot	•	ng Person <sup>*</sup>	2. Issuer Name and Ticker or Trading Symbol Akero Therapeutics, Inc. [ AKRO ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  Director 10% Owner  X Officer (give title Other (specify
(Last) (First) (Middle)		(Middle)	3. Date of Earliest Transaction (Month/Day/Year)	below) below)  Chief Scientific Officer
C/O AKERO T	THERAPEU'	TICS, INC.	11/15/2022	Chief Scientific Officer
601 GATEWAY	Y BOULEVA	ARD, SUITE 350		
(Street) SOUTH SAN FRANCISCO	CA	94080	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line)  X Form filed by One Reporting Person Form filed by More than One Reporting Person
(City)	(State)	(Zip)		
		Table I Non De	rivetive Securities Assuired Disposed of ar Bon	oficially Owned

#### Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1. Title of Security (Instr. 3) 2. Transaction 2A. Deemed 4. Securities Acquired (A) or 5. Amount of 6. Ownership 7. Nature Form: Direct (D) or of Indirect Beneficial Date **Execution Date**, Transaction Disposed Of (D) (Instr. 3, 4 and 5) (Month/Day/Year) if any (Month/Day/Year) Beneficially Code (Instr. Owned Following Ìndirect (I) 8) Ownership (Instr. 4) (Instr. 4) (A) or (D) Transaction(s) Price Code Amount (Instr. 3 and 4) Common Stock 11/15/2022 $S^{(1)}$ \$45.0423(2) 187,784 3,138 D D Common Stock 11/16/2022 $S^{(1)}$ 3.847 D \$45,4534(3) 183,937 D 11/16/2022 **S**(1) 100 D \$46.045 D Common Stock 183 837

### Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) 3. Transaction 3A. Deemed 5. Number | 6. Date Exercisable and | 7. Title and 8. Price of 9. Number of

Security (Instr. 3)	conversion or Exercise Price of Derivative Security	(Month/Day/Year)	if any (Month/Day/Year)	Transaction Code (Instr. 8)		or Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)				Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		Security (Instr. 5)	Securities Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	Form: Direct (D) or Indirect (I) (Instr. 4)	of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				

## **Explanation of Responses:**

- 1. The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated June 25, 2021, previously adopted by the reporting person.
- 2. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from \$45.00 to \$45.15, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4.
- 3. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from \$45.00 to \$45.965, inclusive.

# Remarks:

/s/ Jonathan Young, Attorney-

11/16/2022

in-Fact

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.